𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Switching from pergolide to pramipexole in patients with Parkinson's disease

✍ Scribed by P. A. Hanna; L. Ratkos; W. G. Ondo; J. Jankovic

Publisher
Springer
Year
2001
Tongue
English
Weight
100 KB
Volume
108
Category
Article
ISSN
1435-1463

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Efficacy, safety, and tolerability of ov
Efficacy, safety, and tolerability of overnight switching from immediate- to once daily extended-release pramipexole in early Parkinson's disease
✍ Olivier Rascol; Paolo Barone; Robert A. Hauser; Yoshikuni Mizuno; Werner Poewe; 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 132 KB 👁 1 views

## Abstract The aim of this article is to test the feasibility, in early Parkinson's disease (PD), of an overnight switch from immediate‐release (IR) pramipexole to a new once‐daily extended‐release (ER) formulation. Nonfluctuating patients on pramipexole IR three‐times daily, alone or with levodop

Pergolide versus levodopa monotherapy in
Pergolide versus levodopa monotherapy in early Parkinson's disease patients: The PELMOPET study
✍ Wolfgang H. Oertel; Erik Wolters; Cristina Sampaio; Santiago Gimenez-Roldan; Bru 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 125 KB

## Abstract Dopamine agonists are used as initial treatment in patients with Parkinson's disease (PD) to reduce incidence and severity of motor complications. This paradigm is based on long‐term studies, allowing “rescue” therapy with levodopa. The present strict monotherapy study (PELMOPET, the ac